OnKure Therapeutics, Inc.
OKUR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OKUR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OKUR
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision small-molecule drugs targeting validated cancer drivers, with its lead candidate OKI-219 in clinical trials and a cash position of $166.5M as of June 30, 2026.
Key risk: No revenue and recurring losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for OnKure Therapeutics, Inc..
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision small-molecule drugs targeting validated cancer drivers, with its lead candidate OKI-219 in clinical trials and a cash position of $166.5M as of June 30, 2026.
- OnKure is a clinical-stage biopharmaceutical company using a structure-based drug design platform to develop precision small-molecule drugs for cancers and other diseases [sec_mda · as of 2026-03-12].
- Lead product candidate OKI-219 is being evaluated in an ongoing clinical trial [sec · filed 2024-12-10].
- As of June 30, 2026, the company reported cash and equivalents of $166.5M and shareholders' equity of $56.2M [sec].
- The company has incurred significant net losses since inception and expects expenses to increase as it advances its pipeline [sec · filed 2024-10-08][sec_mda · as of 2026-08-04].
- Management believes existing cash will fund planned operations for at least 12 months from the June 30, 2026 financial statement issuance date [sec_mda · as of 2026-08-04].
What works
- OnKure's structure-based drug design platform aims to selectively target mutated forms of proteins while sparing wild-type, potentially improving efficacy and tolerability [sec_mda · as of 2026-03-12].
- The company has a cash runway of at least 12 months from June 30, 2026, providing a buffer for ongoing clinical development [sec_mda · as of 2026-08-04].
- OnKure is advancing a pipeline beyond OKI-219, including discovery-stage small-molecule programs [sec · filed 2024-10-08].
What to weigh
- OnKure has no revenue from product sales and has incurred significant operating losses since inception [sec_mda · as of 2026-08-04].
- The company expects research and development expenses to increase substantially as it advances OKI-219 and other programs through clinical trials [sec_mda · as of 2026-08-04].
- OnKure will require additional capital to fund future operations, which may not be available on favorable terms [sec · filed 2024-05-13].
- Clinical development is inherently risky; the timing and results of OKI-219 trials are uncertain and may differ from expectations [sec · filed 2024-12-10].
From the filings
Quoted directly from source documents.
OnKure is a clinical-stage biopharmaceutical company focused on precision medicines.
“We are a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases that are underserved by available therapies.”
SEC MD&A · March 12, 2026
OKI-219 is in an ongoing clinical trial.
“OKI-219; the timing of data release for the ongoing clinical trial of OKI-219”
SEC filings · December 10, 2024
Risks & what to watch (4)›
Key risks
- No revenue and recurring losses — OnKure has no product revenue and has incurred significant operating losses since inception, with net loss of $15.3M in Q2 2026 [sec][sec_mda · as of 2026-08-04].
- Need for additional capital — The company will need to raise additional funds to continue operations beyond its current cash runway, with no assurance of favorable terms [sec · filed 2024-05-13].
- Clinical trial uncertainty — OKI-219 is in an ongoing trial; results may differ from expectations, and delays or failures could materially impact the company [sec · filed 2024-12-10].
- Early-stage pipeline — Beyond OKI-219, other programs are at the research stage and may not yield development candidates or reach the clinic [sec · filed 2024-10-08].
What to watch
- Data release from the ongoing OKI-219 clinical trial [sec · filed 2024-12-10].
- Progress of discovery-stage programs and potential announcement of new development candidates [sec · filed 2024-10-08].
- Any equity or debt financing activities, including potential use of the ATM sales agreement [sec_mda · as of 2026-08-04].
- Regulatory updates or milestones related to OKI-219's clinical development [sec · filed 2024-05-13].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run OnKure Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OnKure Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
51.1 months
D/E 0.04 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$82.4M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 3,998,333 | $16.6M |
| acorn capital advisors, llc | 2,839,674 | $11.8M |
| adar1 capital management, llc | 2,434,941 | $10.1M |
| prosight management, lp | 2,154,381 | $8.9M |
| bvf inc/il | 1,978,972 | $8.2M |
| adage capital partners gp, l.l.c. | 1,204,819 | $5.0M |
| vanguard capital management llc | 1,164,954 | $4.8M |
| sio capital management, llc | 1,078,965 | $4.5M |
| nea management company, llc | 478,548 | $2.0M |
| rosalind advisors, inc. | 443,763 | $1.8M |
Showing top 10 of 46 institutional holders of OnKure Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 0.2%
- Days to cover
- 0.1
- Shares short
- 69,494
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OKUR short interestGovernance
Frequently asked questions
What is the AI investment thesis for OnKure Therapeutics, Inc.?
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision small-molecule drugs targeting validated cancer drivers, with its lead candidate OKI-219 in clinical trials and a cash position of $166.5M as of June 30, 2026.
What is OnKure Therapeutics, Inc.'s lead drug candidate?
OnKure Therapeutics, Inc.'s most advanced tracked candidate is mavodelpar (Preclinical) for primary mitochondria myopathy (PMM) due to mitochondrial DNA (mtDNA) defects.
Who is the CEO of OnKure Therapeutics, Inc.?
Dr. Nicholas A. Saccomano Ph.D. is the chief executive officer of OnKure Therapeutics, Inc. (OKUR).
Where is OnKure Therapeutics, Inc. headquartered?
OnKure Therapeutics, Inc. (OKUR) is headquartered in Boulder, CO, United States.
What therapeutic areas does OnKure Therapeutics, Inc. focus on?
OnKure Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.